Progenika Biopharma, a provider in the field of personalised medicine, has obtained the CE mark to sell its LPLchip in Europe, to detect mutations in the lipoprotein lipase (LPL) gene.
According to Progenika Biopharma, the diagnostic test rapidly diagnoses patients with complete and partial lipoprotein lipase deficiency (LPLD) and has been developed under an agreement with Amsterdam Molecular Therapeutics (AMT), which has a gene therapy for patients with LPLD.
Progenika claims that the LPLchip can precisely, quickly and economically detect more than 120 mutations in the LPL gene and the test uses advanced DNAchip technology, which offers reliable and fast diagnosis in a blood or saliva sample.
AMT has developed Glybera, a new genetic treatment for LPLD, which has been filed for marketing authorisation with the European Medicines Agency (EMA) in early 2010.